Flexible Clinical Operations and Site Management Across a Diversified Biotech Portfolio: An Application of Quality by Design and Risk-Based Oversight

Discover how a flexible CRO partnership can help emerging biopharma companies manage complex clinical portfolios while maintaining quality, compliance and operational efficiency.

As clinical development portfolios expand across multiple indications and study phases, maintaining consistent site performance and effective oversight becomes increasingly challenging.

How can sponsors scale clinical operations without proportionally increasing internal resources or compromising trial quality?
Navitas Life Sciences explores this challenge in a featured article published in Applied Clinical Trials.

What Does It Take to Build a More Flexible Clinical Operations Model?
Find out how a phased CRO partnership, supported by Quality by Design (QbD) and risk-based oversight, can help address the growing demands of clinical development.

Access the article to explore:

Scaling without added complexity
Quality built into execution
Smarter clinical oversight
Regulatory alignment

A Real-World Perspective on Clinical Operations

Featuring insights from Navitas Life Sciences experts, this article examines a practical CRO partnership model supporting a multi-indication biotech portfolio.

Discover the operational approach, implementation strategy and lessons that can inform your clinical development decisions.

Access the Full Article.

Authors:

	Sowmya Kaur Executive Vice President Navitas Life Sciences
	Janel Shelton-DeMagnus Senior Director, Clinical Operations Navitas Life Sciences
	Ndimuangu Nchotou Hilton Senior Clinical Research Associate Navitas Life Sciences

Published by Applied Clinical Trials, October 2026